Researchers at the Medical University of Vienna have discovered that the epidermal growth factor receptor (EGFR) influences immune cells within the tumor microenvironment of metastatic colorectal cancer, rather than acting solely on cancer cells. Published in Cell Death & Differentiation, the study suggests that silencing EGFR in myeloid cells—specifically macrophages—slows tumor growth and boosts the immune system’s ability to attack malignant cells.
How does EGFR impact the immune system in cancer?
EGFR is a well-known target for cancer therapies, but its role extends beyond the tumor itself. According to the research team led by Maria Sibilia at the Medical University of Vienna, EGFR acts as a regulator of the tumor-promoting immune landscape. When EGFR is active in myeloid cells, it creates an environment that suppresses T cells—the body’s primary defense against cancer. By silencing this receptor in myeloid cells, researchers observed a reduction in the factors that typically inhibit T cell activity, allowing the immune system to recognize and attack the tumor more effectively.
Macrophages are immune cells that usually protect the body from pathogens. However, in the presence of a tumor, they can be reprogrammed to support cancer growth instead of destroying it.
Why do some patients resist current EGFR-targeted therapies?
While EGFR-inhibiting antibodies are standard care for patients without KRAS mutations, many patients fail to respond or develop resistance over time. The study by Sibilia and colleagues suggests this resistance occurs because traditional therapies may not be addressing the immune-suppressive environment created by myeloid cells. Preclinical models showed that removing EGFR from the cancer cells alone did not produce the same therapeutic slowdown as removing it from the myeloid cells, indicating that the immune system is a critical, often overlooked, component of how these treatments work.
Could THBS1 become a new biomarker for colorectal cancer?
The research identified the protein thrombospondin-1 (THBS1) as a potential indicator of disease progression. Data from patient cohorts revealed that elevated levels of both EGFR and THBS1 correlate with a poorer prognosis. Because THBS1 is released by myeloid cells and interacts with T cells, it serves as a measurable sign of the tumor’s microenvironment. Scientists suggest that in the future, monitoring THBS1 levels could help clinicians better predict how a patient’s disease is evolving or how they might respond to specific immune-modulating treatments.
Comparison: Traditional vs. Immune-Targeted Approaches
| Feature | Traditional EGFR Therapy | New Immune-Modulation Approach |
|---|---|---|
| Primary Target | Cancer cells | Myeloid immune cells |
| Mechanism | Direct growth signal blockage | Reprogramming the tumor microenvironment |
Always discuss the latest clinical trial options with your oncologist, especially if standard EGFR-targeted therapies have stopped working or were not effective initially.
Frequently Asked Questions
What are myeloid cells?
Myeloid cells are a broad category of immune cells that include macrophages. In the context of cancer, they can either fight the tumor or be manipulated by the tumor to help it grow and survive.
Is this treatment currently available for patients?
No. These findings are based on preclinical models and patient cohort data. Further clinical trials are required to determine how to safely and effectively modulate EGFR in human immune cells as a treatment.
What does the discovery of THBS1 mean for patients?
THBS1 may eventually serve as a biomarker. This means doctors could potentially use a simple test to measure THBS1 levels to understand if a patient’s tumor environment is becoming more aggressive, allowing for more personalized treatment plans.
For more updates on cancer research breakthroughs, subscribe to our newsletter or check out our latest articles on advancements in immunotherapy. Have questions about this study? Leave a comment below.
